Swipe om te navigeren naar een ander artikel
The Radiation Therapy Oncology Group (RTOG) conducted a randomized, placebo-controlled trial evaluating the efficacy of GM-CSF in reducing mucosal injury and symptom burden from curative radiotherapy for head and neck (H&N) cancer.
Eligible patients with H&N cancer receiving radiation encompassing ≥50 % of the oral cavity or oropharynx received subcutaneous GM-CSF or placebo. Quality of life (QoL) was assessed using the RTOG-modified University of Washington H&N Symptom Questionnaire at baseline 4, 13, 26, and 48 weeks from radiation initiation.
Of 125 eligible patients, 114 were evaluable for QoL (58 GM-CSF, 56 placebo). Patient demographics, clinical characteristics, and baseline symptom scores were well balanced between the treatment arms. At the end of the acute period (13 weeks), patients in both arms reported negative change in total symptom score indicating increase in symptom burden relative to baseline (mean −18.4 GM-CSF, −20.8 placebo). There was no difference in change in total symptom score (p > 0.05) or change in mucous, pain, eating, or activity domain scores (p > 0.01) between patients in the GM-CSF and placebo arms. Analysis limited to patients treated per protocol or with an acceptable protocol deviation also found no difference in change in total symptom score (p > 0.05) or change in domain scores (p > 0.01) between treatment arms. Provider assessment of acute mucositis during treatment did not correlate with patient-reported mucous domain and total symptom scores (p > 0.05).
GM-CSF administered concurrently during head and neck radiation does not appear to significantly improve patient-reported QoL symptom burden.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Trotti, A., Bellm, L. A., Epstein, J. B., Frame, D., Fuchs, H. J., Gwede, C. K., et al. (2003). Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiotherapy and Oncology, 66(3), 253–262. PubMedCrossRef
Rosenthal, D. I. (2007). Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. The Journal of Supportive Oncology, 5(9 Suppl 4), 23–31. PubMed
Elting, L. S., Cooksley, C. D., Chambers, M. S., & Garden, A. S. (2007). Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. International Journal of Radiation Oncology Biology Physics, 68(4), 1110–1120. CrossRef
List, M. A., Siston, A., Haraf, D., Schumm, P., Kies, M., Stenson, K., et al. (1999). Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination. Journal of Clinical Oncology, 17(3), 1020–1028. PubMed
Nicolatou, O., Sotiropoulou-Lontou, A., Skarlatos, J., Kyprianou, K., Kolitsi, G., & Dardoufas, K. (1998). A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: A preliminary report. International Journal of Radiation Oncology Biology Physics, 42(3), 551–556. CrossRef
Kannan, V., Bapsy, P. P., Anantha, N., Doval, D. C., Vaithianathan, H., Banumathy, G., et al. (1997). Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. International Journal of Radiation Oncology Biology Physics, 37(5), 1005–1010. CrossRef
Chi, K. H., Chen, C. H., Chan, W. K., Chow, K. C., Chen, S. Y., Yen, S. H., et al. (1995). Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. Journal of Clinical Oncology, 13(10), 2620–2628. PubMed
Ryu, J. K., Swann, S., LeVeque, F., Scarantino, C. W., Johnson, D., Chen, A., et al. (2007). The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: A double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. International Journal of Radiation Oncology Biology Physics, 67(3), 643–650. CrossRef
Weymuller, E. A, Jr, Alsarraf, R., Yueh, B., Deleyiannis, F. W., & Coltrera, M. D. (2001). Analysis of the performance characteristics of the University of Washington Quality of Life instrument and its modification (UW-QOL-R). Archives of Otolaryngology: Head and Neck Surgery, 127(5), 489–493. CrossRef
Movsas, B., Scott, C., Langer, C., Werner-Wasik, M., Nicolaou, N., Komaki, R., et al. (2005). Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. Journal of Clinical Oncology, 23(10), 2145–2154. PubMedCrossRef
Le, Q. T., Kim, H. E., Schneider, C. J., Murakozy, G., Skladowski, K., Reinisch, S., et al. (2011). Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: A randomized, placebo-controlled study. Journal of Clinical Oncology, 29(20), 2808–2814. PubMedCrossRef
Henke, M., Alfonsi, M., Foa, P., Giralt, J., Bardet, E., Cerezo, L., et al. (2011). Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: A randomized, placebo-controlled trial. Journal of Clinical Oncology, 29(20), 2815–2820. PubMedCrossRef
Sloan, J. A., Berk, L., Roscoe, J., Fisch, M. J., Shaw, E. G., Wyatt, G., et al. (2007). Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. Journal of Clinical Oncology, 25(32), 5070–5077. PubMedCrossRef
- The impact of concurrent granulocyte–macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial
Karen E. Hoffman
Stephanie L. Pugh
Jennifer L. James
Richard K. Valicenti
David G. Brachman
Lawrence B. Berk
Deborah Watkins Bruner
Lisa A. Kachnic
- Springer International Publishing